Century Therapeutics Net Income
| IPSC Stock | USD 1.93 0.18 10.29% |
As of the 18th of February 2026, Century Therapeutics shows the Mean Deviation of 6.54, risk adjusted performance of 0.1973, and Downside Deviation of 7.75. Century Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Century Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.5788 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -145.6 M | -152.8 M | |
| Net Loss | -150.6 M | -158.1 M | |
| Net Loss | -145.6 M | -152.8 M | |
| Net Loss | (1.45) | (1.52) | |
| Net Income Per E B T | 0.91 | 0.81 |
Century | Net Income | Build AI portfolio with Century Stock |
Analyzing Century Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Century Therapeutics's current valuation and future prospects.
Latest Century Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Century Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Century Therapeutics financial statement analysis. It represents the amount of money remaining after all of Century Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Century Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Century Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (126.57 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Century Net Income Regression Statistics
| Arithmetic Mean | (193,508,197) | |
| Coefficient Of Variation | (34.42) | |
| Mean Deviation | 60,306,827 | |
| Median | (244,769,000) | |
| Standard Deviation | 66,606,223 | |
| Sample Variance | 4436.4T | |
| Range | 191.2M | |
| R-Value | 0.74 | |
| Mean Square Error | 2164.2T | |
| R-Squared | 0.54 | |
| Significance | 0.0007 | |
| Slope | 9,716,471 | |
| Total Sum of Squares | 70982.2T |
Century Net Income History
Other Fundumenentals of Century Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Century Therapeutics Net Income component correlations
Century Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Century Therapeutics is extremely important. It helps to project a fair market value of Century Stock properly, considering its historical fundamentals such as Net Income. Since Century Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Century Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Century Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Century diversify its offerings? Factors like these will boost the valuation of Century Therapeutics. Market participants price Century higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Century Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 126.677 | Return On Assets | Return On Equity |
Investors evaluate Century Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Century Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Century Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Century Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Century Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Century Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Century Therapeutics.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Century Therapeutics on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Century Therapeutics or generate 0.0% return on investment in Century Therapeutics over 90 days. Century Therapeutics is related to or competes with Coeptis Therapeutics, Medicus Pharma, Cue Biopharma, Equillium, Senti Biosciences, Telomir Pharmaceuticals, and OS Therapies. Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment... More
Century Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Century Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Century Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.75 | |||
| Information Ratio | 0.2312 | |||
| Maximum Drawdown | 59.27 | |||
| Value At Risk | (10.94) | |||
| Potential Upside | 14.71 |
Century Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Century Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Century Therapeutics' standard deviation. In reality, there are many statistical measures that can use Century Therapeutics historical prices to predict the future Century Therapeutics' volatility.| Risk Adjusted Performance | 0.1973 | |||
| Jensen Alpha | 2.25 | |||
| Total Risk Alpha | 1.78 | |||
| Sortino Ratio | 0.2923 | |||
| Treynor Ratio | 1.58 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Century Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Century Therapeutics February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1973 | |||
| Market Risk Adjusted Performance | 1.59 | |||
| Mean Deviation | 6.54 | |||
| Semi Deviation | 5.47 | |||
| Downside Deviation | 7.75 | |||
| Coefficient Of Variation | 422.64 | |||
| Standard Deviation | 9.8 | |||
| Variance | 96.11 | |||
| Information Ratio | 0.2312 | |||
| Jensen Alpha | 2.25 | |||
| Total Risk Alpha | 1.78 | |||
| Sortino Ratio | 0.2923 | |||
| Treynor Ratio | 1.58 | |||
| Maximum Drawdown | 59.27 | |||
| Value At Risk | (10.94) | |||
| Potential Upside | 14.71 | |||
| Downside Variance | 60.11 | |||
| Semi Variance | 29.95 | |||
| Expected Short fall | (8.78) | |||
| Skewness | 1.7 | |||
| Kurtosis | 6.02 |
Century Therapeutics Backtested Returns
Century Therapeutics is extremely dangerous given 3 months investment horizon. Century Therapeutics secures Sharpe Ratio (or Efficiency) of 0.28, which signifies that the company had a 0.28 % return per unit of risk over the last 3 months. We are able to interpolate and collect twenty-eight different technical indicators, which can help you to evaluate if expected returns of 2.78% are justified by taking the suggested risk. Use Century Therapeutics Risk Adjusted Performance of 0.1973, mean deviation of 6.54, and Downside Deviation of 7.75 to evaluate company specific risk that cannot be diversified away. Century Therapeutics holds a performance score of 22 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.46, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Century Therapeutics will likely underperform. Use Century Therapeutics sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Century Therapeutics.
Auto-correlation | -0.13 |
Insignificant reverse predictability
Century Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Century Therapeutics time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Century Therapeutics price movement. The serial correlation of -0.13 indicates that less than 13.0% of current Century Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.13 | |
| Spearman Rank Test | -0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Century Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Century Therapeutics reported net income of (126.57 Million). This is 137.09% lower than that of the Biotechnology sector and 280.69% lower than that of the Health Care industry. The net income for all United States stocks is 122.17% higher than that of the company.
Century Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Century Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Century Therapeutics could also be used in its relative valuation, which is a method of valuing Century Therapeutics by comparing valuation metrics of similar companies.Century Therapeutics is currently under evaluation in net income category among its peers.
Century Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Century Therapeutics from analyzing Century Therapeutics' financial statements. These drivers represent accounts that assess Century Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Century Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 872.4M | 296.3M | 196.9M | 79.4M | 91.4M | 86.8M | |
| Enterprise Value | 841.1M | 261.4M | 197.8M | 74.8M | 86.0M | 81.7M |
Century Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Century Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Century Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Century Therapeutics' value.| Shares | Gsa Capital Partners Llp | 2025-06-30 | 466.6 K | Superstring Capital Management Lp | 2025-06-30 | 463 K | Jane Street Group Llc | 2025-06-30 | 444.6 K | Geode Capital Management, Llc | 2025-06-30 | 380.3 K | Two Sigma Advisers, Llc | 2025-06-30 | 367.1 K | Goldman Sachs Group Inc | 2025-06-30 | 276 K | Susquehanna International Group, Llp | 2025-06-30 | 200 K | Citadel Advisors Llc | 2025-06-30 | 186.5 K | Charles Schwab Investment Management Inc | 2025-06-30 | 163.4 K | Bain Capital Life Sciences Investors, Llc | 2025-06-30 | 5.4 M | Vanguard Group Inc | 2025-06-30 | 2.1 M |
Century Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0447 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 65.17 M | ||||
| Shares Outstanding | 87.41 M | ||||
| Shares Owned By Insiders | 25.93 % | ||||
| Shares Owned By Institutions | 74.07 % | ||||
| Number Of Shares Shorted | 3.39 M | ||||
| Price To Earning | 86.08 X | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 1.49 X | ||||
| Revenue | 6.59 M | ||||
| Gross Profit | 7.99 M | ||||
| EBITDA | (111.47 M) | ||||
| Net Income | (126.57 M) | ||||
| Cash And Equivalents | 378.76 M | ||||
| Cash Per Share | 6.43 X | ||||
| Total Debt | 53.83 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.79 X | ||||
| Book Value Per Share | 2.04 X | ||||
| Cash Flow From Operations | (110.14 M) | ||||
| Short Ratio | 1.23 X | ||||
| Earnings Per Share | (0.32) X | ||||
| Price To Earnings To Growth | 0.26 X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 140 | ||||
| Beta | 1.76 | ||||
| Market Capitalization | 168.69 M | ||||
| Total Asset | 353.22 M | ||||
| Retained Earnings | (782.34 M) | ||||
| Working Capital | 64.27 M | ||||
| Net Asset | 353.22 M |
About Century Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Century Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Century Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Century Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:Check out For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Will Biotechnology sector continue expanding? Could Century diversify its offerings? Factors like these will boost the valuation of Century Therapeutics. Market participants price Century higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Century Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 126.677 | Return On Assets | Return On Equity |
Investors evaluate Century Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Century Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Century Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Century Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.